世界のマイコプラズマ・ハイオニューモニエワクチン市場インサイト・予測（～2027年）

• 英文タイトル：Global Mycoplasma Hyopneumoniae Vaccine Market Insights and Forecast to 2027

• レポートコード：QY2108PAL3994 • 出版社/出版日：QYResearch / 2021年8月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Multi User	￥1,087,800 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査資料はマイコプラズマ・ハイオニューモニエワクチンの世界市場の現状について調査・分析し、2027年までの市場を予測しました。マイコプラズマ・ハイオニューモニエワクチンの世界市場概要、メーカー別の競争状況と市場シェア、種類別市場規模（生ワクチン、不活化ワクチン）、用途別市場規模（子豚、成豚）、主要地域別市場規模（北米・アメリカ、ヨーロッパ、アジア・日本・中国・インド、中南米、中東・アフリカ）、関連企業の情報、バリューチェーン・販売チャネル、市場動向などを収録しています。 ・マイコプラズマ・ハイオニューモニエワクチンの世界市場概要 ・メーカー別の競争状況、市場シェア ・マイコプラズマ・ハイオニューモニエワクチンの種類別市場規模：生ワクチン、不活化ワクチン ・マイコプラズマ・ハイオニューモニエワクチンの用途別市場規模：子豚、成豚 ・北米のマイコプラズマ・ハイオニューモニエワクチン市場規模2016-2027：種類別、用途別、国別（アメリカ、カナダ） ・ヨーロッパのマイコプラズマ・ハイオニューモニエワクチン市場規模2016-2027：種類別、用途別、国別（ドイツ、フランス、イギリス） ・アジアのマイコプラズマ・ハイオニューモニエワクチン市場規模2016-2027：種類別、用途別、国別（日本、中国、インド、韓国） ・中南米のマイコプラズマ・ハイオニューモニエワクチン市場規模2016-2027：種類別、用途別、国別（メキシコ、ブラジル） ・中東・アフリカのマイコプラズマ・ハイオニューモニエワクチン市場規模2016-2027：種類別、用途別、国別（トルコ、サウジアラビア） ・企業情報：Zoetis、Merck、Boehringer Ingelheim、Ceva Santé Animale、Elanco Animal Health、Qilu Animal Health、Ruipu、Shanghai Hile Bio-Technology Co., Ltd.、CAHIC、Pulike、Harbin Pharmaceutical Group ・マイコプラズマ・ハイオニューモニエワクチンのバリューチェーン・販売チャネル分析 ・マイコプラズマ・ハイオニューモニエワクチンの世界市場動向

Mycoplasma Hyopneumoniae Vaccine can effectively prevent Mycoplasma suis. Mycoplasma pneumonia has always been regarded as one of the most widespread diseases that cause major economic losses to the pig industry.

Market Analysis and Insights: Global Mycoplasma Hyopneumoniae Vaccine Market
The global Mycoplasma Hyopneumoniae Vaccine market is valued at US$ XX million in 2020. The market size will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.

Global Mycoplasma Hyopneumoniae Vaccine Scope and Segment
Mycoplasma Hyopneumoniae Vaccine market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Mycoplasma Hyopneumoniae Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type
Live
Inactivated

Segment by Application
Piglets
Adult Pigs

By Company
Zoetis
Merck
Boehringer Ingelheim
Ceva Santé Animale
Elanco Animal Health
Qilu Animal Health
Ruipu
Shanghai Hile Bio-Technology Co., Ltd.
CAHIC
Pulike
Harbin Pharmaceutical Group

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Mycoplasma Hyopneumoniae Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Mycoplasma Hyopneumoniae Vaccine Market Size Growth Rate by Type
1.2.2 Live
1.2.3 Inactivated
1.3 Market by Application
1.3.1 Global Mycoplasma Hyopneumoniae Vaccine Market Size Growth Rate by Application
1.3.2 Piglets
1.3.3 Adult Pigs
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Mycoplasma Hyopneumoniae Vaccine Sales Estimates and Forecasts 2016-2027
2.2 Global Mycoplasma Hyopneumoniae Vaccine Revenue Estimates and Forecasts 2016-2027
2.3 Global Mycoplasma Hyopneumoniae Vaccine Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top Mycoplasma Hyopneumoniae Vaccine Regions by Sales
2.4.1 Global Top Mycoplasma Hyopneumoniae Vaccine Regions by Sales (2016-2021)
2.4.2 Global Top Mycoplasma Hyopneumoniae Vaccine Regions by Sales (2022-2027)
2.5 Global Top Mycoplasma Hyopneumoniae Vaccine Regions by Revenue
2.5.1 Global Top Mycoplasma Hyopneumoniae Vaccine Regions by Revenue (2016-2021)
2.5.2 Global Top Mycoplasma Hyopneumoniae Vaccine Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa

3 Competition by Manufacturers
3.1 Global Mycoplasma Hyopneumoniae Vaccine Sales by Manufacturers
3.1.1 Global Top Mycoplasma Hyopneumoniae Vaccine Manufacturers by Sales (2016-2021)
3.1.2 Global Top Mycoplasma Hyopneumoniae Vaccine Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by Mycoplasma Hyopneumoniae Vaccine Sales in 2020
3.2 Global Mycoplasma Hyopneumoniae Vaccine Revenue by Manufacturers
3.2.1 Global Top Mycoplasma Hyopneumoniae Vaccine Manufacturers by Revenue (2016-2021)
3.2.2 Global Top Mycoplasma Hyopneumoniae Vaccine Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by Mycoplasma Hyopneumoniae Vaccine Revenue in 2020
3.3 Global Mycoplasma Hyopneumoniae Vaccine Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Mycoplasma Hyopneumoniae Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Mycoplasma Hyopneumoniae Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Mycoplasma Hyopneumoniae Vaccine Sales by Type
4.1.1 Global Mycoplasma Hyopneumoniae Vaccine Historical Sales by Type (2016-2021)
4.1.2 Global Mycoplasma Hyopneumoniae Vaccine Forecasted Sales by Type (2022-2027)
4.1.3 Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2016-2027)
4.2 Global Mycoplasma Hyopneumoniae Vaccine Revenue by Type
4.2.1 Global Mycoplasma Hyopneumoniae Vaccine Historical Revenue by Type (2016-2021)
4.2.2 Global Mycoplasma Hyopneumoniae Vaccine Forecasted Revenue by Type (2022-2027)
4.2.3 Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2016-2027)
4.3 Global Mycoplasma Hyopneumoniae Vaccine Price by Type
4.3.1 Global Mycoplasma Hyopneumoniae Vaccine Price by Type (2016-2021)
4.3.2 Global Mycoplasma Hyopneumoniae Vaccine Price Forecast by Type (2022-2027)

5 Market Size by Application
5.1 Global Mycoplasma Hyopneumoniae Vaccine Sales by Application
5.1.1 Global Mycoplasma Hyopneumoniae Vaccine Historical Sales by Application (2016-2021)
5.1.2 Global Mycoplasma Hyopneumoniae Vaccine Forecasted Sales by Application (2022-2027)
5.1.3 Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2016-2027)
5.2 Global Mycoplasma Hyopneumoniae Vaccine Revenue by Application
5.2.1 Global Mycoplasma Hyopneumoniae Vaccine Historical Revenue by Application (2016-2021)
5.2.2 Global Mycoplasma Hyopneumoniae Vaccine Forecasted Revenue by Application (2022-2027)
5.2.3 Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2016-2027)
5.3 Global Mycoplasma Hyopneumoniae Vaccine Price by Application
5.3.1 Global Mycoplasma Hyopneumoniae Vaccine Price by Application (2016-2021)
5.3.2 Global Mycoplasma Hyopneumoniae Vaccine Price Forecast by Application (2022-2027)

6 North America
6.1 North America Mycoplasma Hyopneumoniae Vaccine Market Size by Type
6.1.1 North America Mycoplasma Hyopneumoniae Vaccine Sales by Type (2016-2027)
6.1.2 North America Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2016-2027)
6.2 North America Mycoplasma Hyopneumoniae Vaccine Market Size by Application
6.2.1 North America Mycoplasma Hyopneumoniae Vaccine Sales by Application (2016-2027)
6.2.2 North America Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2016-2027)
6.3 North America Mycoplasma Hyopneumoniae Vaccine Market Size by Country
6.3.1 North America Mycoplasma Hyopneumoniae Vaccine Sales by Country (2016-2027)
6.3.2 North America Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2016-2027)
6.3.3 United States
6.3.4 Canada

7 Europe
7.1 Europe Mycoplasma Hyopneumoniae Vaccine Market Size by Type
7.1.1 Europe Mycoplasma Hyopneumoniae Vaccine Sales by Type (2016-2027)
7.1.2 Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2016-2027)
7.2 Europe Mycoplasma Hyopneumoniae Vaccine Market Size by Application
7.2.1 Europe Mycoplasma Hyopneumoniae Vaccine Sales by Application (2016-2027)
7.2.2 Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2016-2027)
7.3 Europe Mycoplasma Hyopneumoniae Vaccine Market Size by Country
7.3.1 Europe Mycoplasma Hyopneumoniae Vaccine Sales by Country (2016-2027)
7.3.2 Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2016-2027)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia

8 Asia Pacific
8.1 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Market Size by Type
8.1.1 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales by Type (2016-2027)
8.1.2 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2016-2027)
8.2 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Market Size by Application
8.2.1 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales by Application (2016-2027)
8.2.2 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2016-2027)
8.3 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Market Size by Region
8.3.1 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales by Region (2016-2027)
8.3.2 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2016-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia

9 Latin America
9.1 Latin America Mycoplasma Hyopneumoniae Vaccine Market Size by Type
9.1.1 Latin America Mycoplasma Hyopneumoniae Vaccine Sales by Type (2016-2027)
9.1.2 Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2016-2027)
9.2 Latin America Mycoplasma Hyopneumoniae Vaccine Market Size by Application
9.2.1 Latin America Mycoplasma Hyopneumoniae Vaccine Sales by Application (2016-2027)
9.2.2 Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2016-2027)
9.3 Latin America Mycoplasma Hyopneumoniae Vaccine Market Size by Country
9.3.1 Latin America Mycoplasma Hyopneumoniae Vaccine Sales by Country (2016-2027)
9.3.2 Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2016-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia

10 Middle East and Africa
10.1 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Market Size by Type
10.1.1 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales by Type (2016-2027)
10.1.2 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2016-2027)
10.2 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Market Size by Application
10.2.1 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales by Application (2016-2027)
10.2.2 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2016-2027)
10.3 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Market Size by Country
10.3.1 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales by Country (2016-2027)
10.3.2 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2016-2027)
10.3.3 Turkey
10.3.4 Saudi Arabia

11 Company Profiles
11.1 Zoetis
11.1.1 Zoetis Corporation Information
11.1.2 Zoetis Overview
11.1.3 Zoetis Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Zoetis Mycoplasma Hyopneumoniae Vaccine Product Description
11.1.5 Zoetis Recent Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Overview
11.2.3 Merck Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 Merck Mycoplasma Hyopneumoniae Vaccine Product Description
11.2.5 Merck Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Overview
11.3.3 Boehringer Ingelheim Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 Boehringer Ingelheim Mycoplasma Hyopneumoniae Vaccine Product Description
11.3.5 Boehringer Ingelheim Recent Developments
11.4 Ceva Santé Animale
11.4.1 Ceva Santé Animale Corporation Information
11.4.2 Ceva Santé Animale Overview
11.4.3 Ceva Santé Animale Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.4.4 Ceva Santé Animale Mycoplasma Hyopneumoniae Vaccine Product Description
11.4.5 Ceva Santé Animale Recent Developments
11.5 Elanco Animal Health
11.5.1 Elanco Animal Health Corporation Information
11.5.2 Elanco Animal Health Overview
11.5.3 Elanco Animal Health Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.5.4 Elanco Animal Health Mycoplasma Hyopneumoniae Vaccine Product Description
11.5.5 Elanco Animal Health Recent Developments
11.6 Qilu Animal Health
11.6.1 Qilu Animal Health Corporation Information
11.6.2 Qilu Animal Health Overview
11.6.3 Qilu Animal Health Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.6.4 Qilu Animal Health Mycoplasma Hyopneumoniae Vaccine Product Description
11.6.5 Qilu Animal Health Recent Developments
11.7 Ruipu
11.7.1 Ruipu Corporation Information
11.7.2 Ruipu Overview
11.7.3 Ruipu Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.7.4 Ruipu Mycoplasma Hyopneumoniae Vaccine Product Description
11.7.5 Ruipu Recent Developments
11.8 Shanghai Hile Bio-Technology Co., Ltd.
11.8.1 Shanghai Hile Bio-Technology Co., Ltd. Corporation Information
11.8.2 Shanghai Hile Bio-Technology Co., Ltd. Overview
11.8.3 Shanghai Hile Bio-Technology Co., Ltd. Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.8.4 Shanghai Hile Bio-Technology Co., Ltd. Mycoplasma Hyopneumoniae Vaccine Product Description
11.8.5 Shanghai Hile Bio-Technology Co., Ltd. Recent Developments
11.9 CAHIC
11.9.1 CAHIC Corporation Information
11.9.2 CAHIC Overview
11.9.3 CAHIC Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.9.4 CAHIC Mycoplasma Hyopneumoniae Vaccine Product Description
11.9.5 CAHIC Recent Developments
11.10 Pulike
11.10.1 Pulike Corporation Information
11.10.2 Pulike Overview
11.10.3 Pulike Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.10.4 Pulike Mycoplasma Hyopneumoniae Vaccine Product Description
11.10.5 Pulike Recent Developments
11.11 Harbin Pharmaceutical Group
11.11.1 Harbin Pharmaceutical Group Corporation Information
11.11.2 Harbin Pharmaceutical Group Overview
11.11.3 Harbin Pharmaceutical Group Mycoplasma Hyopneumoniae Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.11.4 Harbin Pharmaceutical Group Mycoplasma Hyopneumoniae Vaccine Product Description
11.11.5 Harbin Pharmaceutical Group Recent Developments

12 Value Chain and Sales Channels Analysis
12.1 Mycoplasma Hyopneumoniae Vaccine Value Chain Analysis
12.2 Mycoplasma Hyopneumoniae Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Mycoplasma Hyopneumoniae Vaccine Production Mode & Process
12.4 Mycoplasma Hyopneumoniae Vaccine Sales and Marketing
12.4.1 Mycoplasma Hyopneumoniae Vaccine Sales Channels
12.4.2 Mycoplasma Hyopneumoniae Vaccine Distributors
12.5 Mycoplasma Hyopneumoniae Vaccine Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Mycoplasma Hyopneumoniae Vaccine Industry Trends
13.2 Mycoplasma Hyopneumoniae Vaccine Market Drivers
13.3 Mycoplasma Hyopneumoniae Vaccine Market Challenges
13.4 Mycoplasma Hyopneumoniae Vaccine Market Restraints

14 Key Findings in The Global Mycoplasma Hyopneumoniae Vaccine Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Mycoplasma Hyopneumoniae Vaccine Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Live
Table 3. Major Manufacturers of Inactivated
Table 4. Global Mycoplasma Hyopneumoniae Vaccine Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
Table 5. Global Mycoplasma Hyopneumoniae Vaccine Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
Table 6. Global Mycoplasma Hyopneumoniae Vaccine Sales by Region (2016-2021) & (K Units)
Table 7. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2016-2021)
Table 8. Global Mycoplasma Hyopneumoniae Vaccine Sales by Region (2022-2027) & (K Units)
Table 9. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2022-2027)
Table 10. Global Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2016-2021) & (US$ Million)
Table 11. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Region (2016-2021)
Table 12. Global Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2022-2027) & (US$ Million)
Table 13. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Region (2022-2027)
Table 14. Global Mycoplasma Hyopneumoniae Vaccine Sales by Manufacturers (2016-2021) & (K Units)
Table 15. Global Mycoplasma Hyopneumoniae Vaccine Sales Share by Manufacturers (2016-2021)
Table 16. Global Mycoplasma Hyopneumoniae Vaccine Revenue by Manufacturers (2016-2021) & (US$ Million)
Table 17. Global Mycoplasma Hyopneumoniae Vaccine Revenue Share by Manufacturers (2016-2021)
Table 18. Mycoplasma Hyopneumoniae Vaccine Price by Manufacturers 2016-2021 (US$/Unit)
Table 19. Global Mycoplasma Hyopneumoniae Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Mycoplasma Hyopneumoniae Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mycoplasma Hyopneumoniae Vaccine as of 2020)
Table 21. Mycoplasma Hyopneumoniae Vaccine Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Mycoplasma Hyopneumoniae Vaccine Product Offered
Table 23. Date of Manufacturers Enter into Mycoplasma Hyopneumoniae Vaccine Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Mycoplasma Hyopneumoniae Vaccine Sales by Type (2016-2021) & (K Units)
Table 26. Global Mycoplasma Hyopneumoniae Vaccine Sales by Type (2022-2027) & (K Units)
Table 27. Global Mycoplasma Hyopneumoniae Vaccine Sales Share by Type (2016-2021)
Table 28. Global Mycoplasma Hyopneumoniae Vaccine Sales Share by Type (2022-2027)
Table 29. Global Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2016-2021) & (US$ Million)
Table 30. Global Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2022-2027) & (US$ Million)
Table 31. Global Mycoplasma Hyopneumoniae Vaccine Revenue Share by Type (2016-2021)
Table 32. Global Mycoplasma Hyopneumoniae Vaccine Revenue Share by Type (2022-2027)
Table 33. Mycoplasma Hyopneumoniae Vaccine Price by Type (2016-2021) & (US$/Unit)
Table 34. Global Mycoplasma Hyopneumoniae Vaccine Price Forecast by Type (2022-2027) & (US$/Unit)
Table 35. Global Mycoplasma Hyopneumoniae Vaccine Sales by Application (2016-2021) & (K Units)
Table 36. Global Mycoplasma Hyopneumoniae Vaccine Sales by Application (2022-2027) & (K Units)
Table 37. Global Mycoplasma Hyopneumoniae Vaccine Sales Share by Application (2016-2021)
Table 38. Global Mycoplasma Hyopneumoniae Vaccine Sales Share by Application (2022-2027)
Table 39. Global Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2016-2021) & (US$ Million)
Table 40. Global Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2022-2027) & (US$ Million)
Table 41. Global Mycoplasma Hyopneumoniae Vaccine Revenue Share by Application (2016-2021)
Table 42. Global Mycoplasma Hyopneumoniae Vaccine Revenue Share by Application (2022-2027)
Table 43. Mycoplasma Hyopneumoniae Vaccine Price by Application (2016-2021) & (US$/Unit)
Table 44. Global Mycoplasma Hyopneumoniae Vaccine Price Forecast by Application (2022-2027) & (US$/Unit)
Table 45. North America Mycoplasma Hyopneumoniae Vaccine Sales by Type (2016-2021) & (K Units)
Table 46. North America Mycoplasma Hyopneumoniae Vaccine Sales by Type (2022-2027) & (K Units)
Table 47. North America Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2016-2021) & (US$ Million)
Table 48. North America Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2022-2027) & (US$ Million)
Table 49. North America Mycoplasma Hyopneumoniae Vaccine Sales by Application (2016-2021) & (K Units)
Table 50. North America Mycoplasma Hyopneumoniae Vaccine Sales by Application (2022-2027) & (K Units)
Table 51. North America Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2016-2021) & (US$ Million)
Table 52. North America Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2022-2027) & (US$ Million)
Table 53. North America Mycoplasma Hyopneumoniae Vaccine Sales by Country (2016-2021) & (K Units)
Table 54. North America Mycoplasma Hyopneumoniae Vaccine Sales by Country (2022-2027) & (K Units)
Table 55. North America Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 56. North America Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 57. Europe Mycoplasma Hyopneumoniae Vaccine Sales by Type (2016-2021) & (K Units)
Table 58. Europe Mycoplasma Hyopneumoniae Vaccine Sales by Type (2022-2027) & (K Units)
Table 59. Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2016-2021) & (US$ Million)
Table 60. Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2022-2027) & (US$ Million)
Table 61. Europe Mycoplasma Hyopneumoniae Vaccine Sales by Application (2016-2021) & (K Units)
Table 62. Europe Mycoplasma Hyopneumoniae Vaccine Sales by Application (2022-2027) & (K Units)
Table 63. Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2016-2021) & (US$ Million)
Table 64. Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2022-2027) & (US$ Million)
Table 65. Europe Mycoplasma Hyopneumoniae Vaccine Sales by Country (2016-2021) & (K Units)
Table 66. Europe Mycoplasma Hyopneumoniae Vaccine Sales by Country (2022-2027) & (K Units)
Table 67. Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 68. Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 69. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales by Type (2016-2021) & (K Units)
Table 70. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales by Type (2022-2027) & (K Units)
Table 71. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2016-2021) & (US$ Million)
Table 72. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2022-2027) & (US$ Million)
Table 73. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales by Application (2016-2021) & (K Units)
Table 74. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales by Application (2022-2027) & (K Units)
Table 75. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2016-2021) & (US$ Million)
Table 76. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2022-2027) & (US$ Million)
Table 77. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales by Region (2016-2021) & (K Units)
Table 78. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales by Region (2022-2027) & (K Units)
Table 79. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2016-2021) & (US$ Million)
Table 80. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2022-2027) & (US$ Million)
Table 81. Latin America Mycoplasma Hyopneumoniae Vaccine Sales by Type (2016-2021) & (K Units)
Table 82. Latin America Mycoplasma Hyopneumoniae Vaccine Sales by Type (2022-2027) & (K Units)
Table 83. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2016-2021) & (US$ Million)
Table 84. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2022-2027) & (US$ Million)
Table 85. Latin America Mycoplasma Hyopneumoniae Vaccine Sales by Application (2016-2021) & (K Units)
Table 86. Latin America Mycoplasma Hyopneumoniae Vaccine Sales by Application (2022-2027) & (K Units)
Table 87. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2016-2021) & (US$ Million)
Table 88. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2022-2027) & (US$ Million)
Table 89. Latin America Mycoplasma Hyopneumoniae Vaccine Sales by Country (2016-2021) & (K Units)
Table 90. Latin America Mycoplasma Hyopneumoniae Vaccine Sales by Country (2022-2027) & (K Units)
Table 91. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 92. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 93. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales by Type (2016-2021) & (K Units)
Table 94. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales by Type (2022-2027) & (K Units)
Table 95. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2016-2021) & (US$ Million)
Table 96. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2022-2027) & (US$ Million)
Table 97. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales by Application (2016-2021) & (K Units)
Table 98. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales by Application (2022-2027) & (K Units)
Table 99. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2016-2021) & (US$ Million)
Table 100. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2022-2027) & (US$ Million)
Table 101. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales by Country (2016-2021) & (K Units)
Table 102. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales by Country (2022-2027) & (K Units)
Table 103. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 104. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 105. Zoetis Corporation Information
Table 106. Zoetis Description and Major Businesses
Table 107. Zoetis Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 108. Zoetis Mycoplasma Hyopneumoniae Vaccine Product
Table 109. Zoetis Recent Developments
Table 110. Merck Corporation Information
Table 111. Merck Description and Major Businesses
Table 112. Merck Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 113. Merck Mycoplasma Hyopneumoniae Vaccine Product
Table 114. Merck Recent Developments
Table 115. Boehringer Ingelheim Corporation Information
Table 116. Boehringer Ingelheim Description and Major Businesses
Table 117. Boehringer Ingelheim Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 118. Boehringer Ingelheim Mycoplasma Hyopneumoniae Vaccine Product
Table 119. Boehringer Ingelheim Recent Developments
Table 120. Ceva Santé Animale Corporation Information
Table 121. Ceva Santé Animale Description and Major Businesses
Table 122. Ceva Santé Animale Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 123. Ceva Santé Animale Mycoplasma Hyopneumoniae Vaccine Product
Table 124. Ceva Santé Animale Recent Developments
Table 125. Elanco Animal Health Corporation Information
Table 126. Elanco Animal Health Description and Major Businesses
Table 127. Elanco Animal Health Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 128. Elanco Animal Health Mycoplasma Hyopneumoniae Vaccine Product
Table 129. Elanco Animal Health Recent Developments
Table 130. Qilu Animal Health Corporation Information
Table 131. Qilu Animal Health Description and Major Businesses
Table 132. Qilu Animal Health Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 133. Qilu Animal Health Mycoplasma Hyopneumoniae Vaccine Product
Table 134. Qilu Animal Health Recent Developments
Table 135. Ruipu Corporation Information
Table 136. Ruipu Description and Major Businesses
Table 137. Ruipu Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 138. Ruipu Mycoplasma Hyopneumoniae Vaccine Product
Table 139. Ruipu Recent Developments
Table 140. Shanghai Hile Bio-Technology Co., Ltd. Corporation Information
Table 141. Shanghai Hile Bio-Technology Co., Ltd. Description and Major Businesses
Table 142. Shanghai Hile Bio-Technology Co., Ltd. Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 143. Shanghai Hile Bio-Technology Co., Ltd. Mycoplasma Hyopneumoniae Vaccine Product
Table 144. Shanghai Hile Bio-Technology Co., Ltd. Recent Developments
Table 145. CAHIC Corporation Information
Table 146. CAHIC Description and Major Businesses
Table 147. CAHIC Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 148. CAHIC Mycoplasma Hyopneumoniae Vaccine Product
Table 149. CAHIC Recent Developments
Table 150. Pulike Corporation Information
Table 151. Pulike Description and Major Businesses
Table 152. Pulike Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 153. Pulike Mycoplasma Hyopneumoniae Vaccine Product
Table 154. Pulike Recent Developments
Table 155. Harbin Pharmaceutical Group Corporation Information
Table 156. Harbin Pharmaceutical Group Description and Major Businesses
Table 157. Harbin Pharmaceutical Group Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 158. Harbin Pharmaceutical Group Mycoplasma Hyopneumoniae Vaccine Product
Table 159. Harbin Pharmaceutical Group Recent Developments
Table 160. Key Raw Materials Lists
Table 161. Raw Materials Key Suppliers Lists
Table 162. Mycoplasma Hyopneumoniae Vaccine Distributors List
Table 163. Mycoplasma Hyopneumoniae Vaccine Customers List
Table 164. Mycoplasma Hyopneumoniae Vaccine Market Trends
Table 165. Mycoplasma Hyopneumoniae Vaccine Market Drivers
Table 166. Mycoplasma Hyopneumoniae Vaccine Market Challenges
Table 167. Mycoplasma Hyopneumoniae Vaccine Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Mycoplasma Hyopneumoniae Vaccine Product Picture
Figure 2. Global Mycoplasma Hyopneumoniae Vaccine Market Share by Type in 2020 & 2027
Figure 3. Live Product Picture
Figure 4. Inactivated Product Picture
Figure 5. Global Mycoplasma Hyopneumoniae Vaccine Market Share by Application in 2020 & 2027
Figure 6. Piglets
Figure 7. Adult Pigs
Figure 8. Mycoplasma Hyopneumoniae Vaccine Report Years Considered
Figure 9. Global Mycoplasma Hyopneumoniae Vaccine Sales 2016-2027 (K Units)
Figure 10. Global Mycoplasma Hyopneumoniae Vaccine Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Mycoplasma Hyopneumoniae Vaccine Revenue 2016-2027 (US$ Million)
Figure 12. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Region in Percentage: 2020 Versus 2027
Figure 13. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2016-2021)
Figure 14. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2022-2027)
Figure 15. North America Mycoplasma Hyopneumoniae Vaccine Sales YoY (2016-2027) & (K Units)
Figure 16. North America Mycoplasma Hyopneumoniae Vaccine Revenue YoY (2016-2027) & (US$ Million)
Figure 17. Europe Mycoplasma Hyopneumoniae Vaccine Sales YoY (2016-2027) & (K Units)
Figure 18. Europe Mycoplasma Hyopneumoniae Vaccine Revenue YoY (2016-2027) & (US$ Million)
Figure 19. Asia-Pacific Mycoplasma Hyopneumoniae Vaccine Sales YoY (2016-2027) & (K Units)
Figure 20. Asia-Pacific Mycoplasma Hyopneumoniae Vaccine Revenue YoY (2016-2027) & (US$ Million)
Figure 21. Latin America Mycoplasma Hyopneumoniae Vaccine Sales YoY (2016-2027) & (K Units)
Figure 22. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue YoY (2016-2027) & (US$ Million)
Figure 23. Middle East & Africa Mycoplasma Hyopneumoniae Vaccine Sales YoY (2016-2027) & (K Units)
Figure 24. Middle East & Africa Mycoplasma Hyopneumoniae Vaccine Revenue YoY (2016-2027) & (US$ Million)
Figure 25. The Top 10 and Top 5 Players Market Share by Mycoplasma Hyopneumoniae Vaccine Sales in 2020
Figure 26. The Top 10 and Top 5 Players Market Share by Mycoplasma Hyopneumoniae Vaccine Revenue in 2020
Figure 27. Mycoplasma Hyopneumoniae Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
Figure 28. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2016-2027)
Figure 29. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2016-2027)
Figure 30. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2016-2027)
Figure 31. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2016-2027)
Figure 32. North America Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2016-2027)
Figure 33. North America Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2016-2027)
Figure 34. North America Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2016-2027)
Figure 35. North America Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2016-2027)
Figure 36. North America Mycoplasma Hyopneumoniae Vaccine Sales Share by Country (2016-2027)
Figure 37. North America Mycoplasma Hyopneumoniae Vaccine Revenue Share by Country (2016-2027)
Figure 38. United States Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 39. Canada Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 40. Europe Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2016-2027)
Figure 41. Europe Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2016-2027)
Figure 42. Europe Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2016-2027)
Figure 43. Europe Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2016-2027)
Figure 44. Europe Mycoplasma Hyopneumoniae Vaccine Sales Share by Country (2016-2027)
Figure 45. Europe Mycoplasma Hyopneumoniae Vaccine Revenue Share by Country (2016-2027)
Figure 46. Germany Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 47. France Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 48. U.K. Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 49. Italy Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 50. Russia Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 51. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2016-2027)
Figure 52. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2016-2027)
Figure 53. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2016-2027)
Figure 54. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2016-2027)
Figure 55. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales Share by Region (2016-2027)
Figure 56. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue Share by Region (2016-2027)
Figure 57. China Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 58. Japan Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 59. South Korea Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 60. India Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 61. Australia Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 62. China Taiwan Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 63. Indonesia Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 64. Thailand Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 65. Malaysia Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 66. Latin America Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2016-2027)
Figure 67. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2016-2027)
Figure 68. Latin America Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2016-2027)
Figure 69. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2016-2027)
Figure 70. Latin America Mycoplasma Hyopneumoniae Vaccine Sales Share by Country (2016-2027)
Figure 71. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue Share by Country (2016-2027)
Figure 72. Mexico Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 73. Brazil Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 74. Argentina Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 75. Colombia Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 76. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2016-2027)
Figure 77. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2016-2027)
Figure 78. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2016-2027)
Figure 79. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2016-2027)
Figure 80. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales Share by Country (2016-2027)
Figure 81. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue Share by Country (2016-2027)
Figure 82. Turkey Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 83. Saudi Arabia Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 84. UAE Mycoplasma Hyopneumoniae Vaccine Revenue (2016-2027) & (US$ Million)
Figure 85. Mycoplasma Hyopneumoniae Vaccine Value Chain
Figure 86. Mycoplasma Hyopneumoniae Vaccine Production Process
Figure 87. Channels of Distribution
Figure 88. Distributors Profiles
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed

---